^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Nivolumab for advanced nonsquamous non-small-cell lung cancer after chemotherapy
Excerpt:
Nivolumab is recommended as an option for treating locally advanced or metastatic non-squamous non-small-cell lung cancer (NSCLC) in adults after chemotherapy, only if...their tumours are PD-L1 positive...
Source:
Title:
ivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
Excerpt:
Overall survival was longer with nivolumab than with docetaxel. The median overall survival was 12.2 months (95% confidence interval [CI], 9.7 to 15.0) among 292 patients in the nivolumab group and 9.4 months (95% CI, 8.1 to 10.7) among 290 patients in the docetaxel group...Nivolumab was associated with even greater efficacy than docetaxel across all end points in subgroups defined according to prespecified levels of tumor-membrane expression (≥1%, ≥5%, and ≥10%) of the PD-1 ligand.
DOI:
10.1056/NEJMoa1507643
Trial ID:
Title:
Bristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expression ≥1%
Excerpt:
Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab) in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable non-small cell lung cancer (NSCLC) at high risk of recurrence in adult patients with tumor cell PD-L1 expression ≥1%....The EC’s decision is based on results from the Phase 3 CheckMate -816 trial, in which three cycles of Opdivo with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in event-free survival (EFS) and pathologic complete response (pCR) compared to chemotherapy alone when administered before surgery.
Source:
Title:
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
Excerpt:
...Progression-Free Survival in Participants With PD-L1 Expression >= 5%...
Trial ID:
Source:
Title:
Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC
Excerpt:
...Objective Response Rate (ORR)`Time To Objective Response (TTOR)`Duration of Objective Response (DOOR)`Progression-Free Survival (PFS)`Percentage of Participants Experiencing Disease-Related Symptom Improvement by Week 12`Overall Survival (OS) by PD-L1 Expression at Baseline`Objective Response Rate (ORR) by PD-L1 Expression at Baseline...
Trial ID:
